<DOC>
	<DOCNO>NCT01508156</DOCNO>
	<brief_summary>The purpose study test safety tolerability different dos IDX719 find best dose future study . The study also assess pharmacokinetics IDX719 . No formal hypothesis test .</brief_summary>
	<brief_title>Study Hepatitis C Virus ( HCV ) Nonstructural Protein 5a ( NS5A ) Inhibitor IDX719 Healthy HCV-Infected Participants ( MK-1894-001 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>All Participants Is good general health . Agrees use doublebarrier method birth control least 90 day last dose study drug . HCV Participants Has document GT1 , GT2 , GT3 chronic HCV infection . All Participants Is pregnant breastfeeding . HCV Participants Has receive prior HCV treatment . Is coinfected hepatitis B virus ( HBV ) and/or human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>treatment-naive</keyword>
</DOC>